Dan Li1, Hui Li, Hong Shi. 1. Department of Pediatric Hematology and Oncology, Chengdu Women and Children's Central Hospital, Chengdu 610091, China. lidan0420@sina.com.
Abstract
OBJECTIVE: To investigate the clinical features and prognosis of children with Langerhans cell histiocytosis (LCH). METHODS: A retrospective analysis was performed for the clinical data of 34 children with newly diagnosed LCH. RESULTS: The 34 children had a median age of 14.5 months (range: 22 d to 60 months). Of all 34 children, 23 were aged 0-2 years and 11 were aged >2 years. There were 17 children in the high-risk group and 17 in the low-risk group. Thirty children received chemotherapy, and the 6-week and 12-month overall response rates were 67% (20/30) and 87% (26/30), respectively. The 3-year overall survival (OS) rate was 86%±6% and the 3-year event-free survival (EFS) rate was 64%±9%. Compared with the low-risk group, the high-risk group had significantly lower 6-week chemotherapy response rate (47% vs 87%; P<0.05), 3-year OS rate (72%±12% vs 100%; P<0.05), and 3-year EFS rate (46%±13% vs 82%±9%; P<0.05). There was no significant difference in the 12-month chemotherapy response rate between the high-risk and low-risk groups (80% vs 93; P>0.05). The high-risk group had a recurrence rate of 27% and a mortality rate of 27%. There were no recurrence or deaths in the low-risk group. CONCLUSIONS: Children with LCH have a high overall survival rate, but the high-risk patient has a low 6-week response rate of induction chemotherapy and poor long-term prognosis.
OBJECTIVE: To investigate the clinical features and prognosis of children with Langerhans cell histiocytosis (LCH). METHODS: A retrospective analysis was performed for the clinical data of 34 children with newly diagnosed LCH. RESULTS: The 34 children had a median age of 14.5 months (range: 22 d to 60 months). Of all 34 children, 23 were aged 0-2 years and 11 were aged >2 years. There were 17 children in the high-risk group and 17 in the low-risk group. Thirty children received chemotherapy, and the 6-week and 12-month overall response rates were 67% (20/30) and 87% (26/30), respectively. The 3-year overall survival (OS) rate was 86%±6% and the 3-year event-free survival (EFS) rate was 64%±9%. Compared with the low-risk group, the high-risk group had significantly lower 6-week chemotherapy response rate (47% vs 87%; P<0.05), 3-year OS rate (72%±12% vs 100%; P<0.05), and 3-year EFS rate (46%±13% vs 82%±9%; P<0.05). There was no significant difference in the 12-month chemotherapy response rate between the high-risk and low-risk groups (80% vs 93; P>0.05). The high-risk group had a recurrence rate of 27% and a mortality rate of 27%. There were no recurrence or deaths in the low-risk group. CONCLUSIONS:Children with LCH have a high overall survival rate, but the high-risk patient has a low 6-week response rate of induction chemotherapy and poor long-term prognosis.
Authors: F Bernard; C Thomas; Y Bertrand; M Munzer; J Landman Parker; M Ouache; V Minard Colin; Y Perel; P Chastagner; C Vermylen; J Donadieu Journal: Eur J Cancer Date: 2005-04-07 Impact factor: 9.162
Authors: Georgina V Long; Daniil Stroyakovskiy; Helen Gogas; Evgeny Levchenko; Filippo de Braud; James Larkin; Claus Garbe; Thomas Jouary; Axel Hauschild; Jean-Jacques Grob; Vanna Chiarion-Sileni; Celeste Lebbe; Mario Mandalà; Michael Millward; Ana Arance; Igor Bondarenko; John B A G Haanen; Johan Hansson; Jochen Utikal; Virginia Ferraresi; Nadezhda Kovalenko; Peter Mohr; Volodymr Probachai; Dirk Schadendorf; Paul Nathan; Caroline Robert; Antoni Ribas; Douglas J DeMarini; Jhangir G Irani; Suzanne Swann; Jeffrey J Legos; Fan Jin; Bijoyesh Mookerjee; Keith Flaherty Journal: Lancet Date: 2015-05-31 Impact factor: 79.321
Authors: N Grois; U Pötschger; H Prosch; M Minkov; M Arico; J Braier; J-I Henter; G Janka-Schaub; S Ladisch; J Ritter; M Steiner; E Unger; H Gadner Journal: Pediatr Blood Cancer Date: 2006-02 Impact factor: 3.167
Authors: Carl E Allen; Liunan Li; Tricia L Peters; Hon-Chiu Eastwood Leung; Alexander Yu; Tsz-Kwong Man; Sivashankarappa Gurusiddappa; Michelle T Phillips; M John Hicks; Amos Gaikwad; Miriam Merad; Kenneth L McClain Journal: J Immunol Date: 2010-03-10 Impact factor: 5.422
Authors: H Gadner; N Grois; M Arico; V Broadbent; A Ceci; A Jakobson; D Komp; J Michaelis; S Nicholson; U Pötschger; J Pritchard; S Ladisch Journal: J Pediatr Date: 2001-05 Impact factor: 4.406
Authors: Sheila Weitzman; Jorge Braier; Jean Donadieu; R Maarten Egeler; Nicole Grois; Stephan Ladisch; Ulrike Pötschger; David Webb; James Whitlock; Robert J Arceci Journal: Pediatr Blood Cancer Date: 2009-12-15 Impact factor: 3.167